2015 Fiscal Year Final Research Report
Development of novel immunotherapy for malignant melanoma by targeting MDSC.
Project/Area Number |
25461682
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | Tohoku University |
Principal Investigator |
Fujimura Taku 東北大学, 医学(系)研究科(研究院), 助教 (50396496)
|
Co-Investigator(Kenkyū-buntansha) |
Aiba SETSUYA 東北大学, 医学系研究科, 教授 (80159269)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Keywords | 腫瘍随伴マクロファージ / 制御性T細胞 / MDSC / 悪性黒色腫 / PD-L1 / ケモカイン |
Outline of Final Research Achievements |
Our present study revealed that, not only the expression of PD-L1, but also the production of chemokine is important to modify the immunosuppressive microenvironment in B16F10 melanoma model. In addition, on human M2 macrophages, the expression of PD-L1 could be decreased by the treatment of several immune therapy for metastatic melanoma. We published these data at Oncoimmunology in 2015. Moreover, we further investigated tumor-associated macrophages in the series of skin tumor, including invasive and non-invasive extramammary Paget's disease and mycosis fungicides. These data was published at Journal of Investigative Dermatology and Experimental Dermatology in 2015 and 2016.
|
Free Research Field |
皮膚科
|